The recent proliferation of community-acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA) has led to a marked increase in the need for outpatient treatment of MRSA infections. Many oral agents active against MRSA have been available for years, and a paucity of literature compares them, leaving physicians with little guidance for choosing among them. The purpose of the present study was to compare the bactericidal effects of orally available antibiotics against MRSA and to determine whether there were differences in antimicrobial killing activity against CA-MRSA and hospital-acquired (HA) MRSA isolates.
Introduction
Once mainly confined to the healthcare setting, methicillinresistant Staphylococcus aureus (MRSA) has emerged as a prominent cause of skin and soft-tissue infections in the community. 1 Community-acquired MRSA (CA-MRSA) infections may be highly aggressive perhaps related to the nearly uniform presence of genes encoding Panton-Valentine leucocidin. 1 Hence, rapidly acting oral antibiotics for the treatment of MRSA infections in the outpatient setting are needed.
There is a dearth of published data regarding the relative efficacy of the currently available oral antimicrobials against MRSA. In this investigation, we studied the in vitro bactericidal activity of six orally available antistaphylococcal antimicrobials 
Materials and methods
A total of 12 well-characterized strains of MRSA isolated from unique patients were selected for the study. 2 Strains were classified epidemiologically as CA or hospital-acquired (HA) according to CDC guidelines.
MICs of oxacillin, trimethoprim/sulfamethoxazole and clindamycin were assayed with the VITEK system (BioMerieux). Clindamycin susceptibility was confirmed using the double-disc diffusion test. In vitro susceptibilities of linezolid, minocycline and rifampicin were determined by tube dilution according to CLSI standards.
3 Susceptibilities to moxifloxacin were determined using the moxifloxacin Etest.
Bactericidal activity was studied using antimicrobial agents singly and in combination at the following concentrations: linezolid, 8 mg/L; rifampicin, 1 mg/L; trimethoprim/sulfamethoxazole, 1/20 mg/L; amoxicillin/clavulanate, 8/2 mg/L; clindamycin, 2 mg/L; minocycline, 1 mg/L; moxifloxacin, 2 mg/L. The concentration for each agent was chosen carefully to reflect its serum level mid-way between the peak and trough concentration based on conventional oral dosing and pharmacokinetics. We felt that for in vitro studies with concentration-dependent antibiotics with no post-antibiotic effect, these represent the most clinically relevant concentrations. Except for amoxicillin/clavulanate, we tested antibacterial efficacy of antibiotics against susceptible strains only. Time-kill studies were performed in Mueller-Hinton broth containing calcium (25 mg/L) and magnesium (12.5 mg/L) at 37 C with a starting inoculum of 2 · 10 6 cfu/mL. At times 0, 4, 8, 24 and 48 h, aliquots were removed, serially diluted in PBS and plated onto Mueller-Hinton agar to quantify cfu/mL. These time-kill experiments were performed in duplicate for all isolates at all time points. For the purposes of this study, bactericidal activity was defined as a ‡3 log 10 /mL decrease in bacterial counts at 24 h. Synergy was defined as ‡2 log 10 /mL reduction in cfu with the combination as compared with the single more active agent at 24 h. Antagonism was said to be present if the cfu was ‡2 log 10 /mL higher after incubation with the combination than with the single more active agent at 24 h.
Plug preparation, restriction enzyme digestion with SmaI and PFGE were performed, with the patterns interpreted according to established guidelines. 4 Staphylococcal chromosomal cassette mec (SCCmec) type was determined as described previously. 2 Statistical analysis was performed using NCSS, 2004 version. Student's paired t-test was used to evaluate differences for logtransformed residual bacterial counts comparing drugs and/or drug combinations.
Results
Of the 12 MRSA analysed in the present study, 6 CA-MRSA strains were recovered from patients who had skin and/or softtissue infections; all carried SCCmec type IVa. Six HA-MRSA were isolated from hospitalized patients with bacteraemia; all carried SCCmec type II. By PFGE, the CA-MRSA were variants of the same clone while the HA strains consisted of two different clones. The major difference in antibiotic susceptibility between the type II and type IVa SCCmec isolates was observed with clindamycin (0% susceptible versus 100% susceptible, P < 0.001). Consistent with hospital-wide antimicrobial susceptibility patterns, only 3 of the 12 isolates were susceptible to moxifloxacin.
Time-kill studies
The mean decreases in cfu at 4, 8 and 24 h for each antibiotic or antibiotic combination are shown in Table 1 . Time-kill curves for selected antibiotics are shown in Figure 1 . Trimethoprim/ sulfamethoxazole was rapidly bactericidal in vitro, with >2 log 10 reduction in cfu/mL at 8 h and >3 log 10 reduction in cfu/mL at 24 h. Linezolid, minocycline and rifampicin resulted in 0.8-1.5 log 10 reductions in cfu/mL at 24 h. Clindamycin resulted in no decrease in cfu/mL at 24 h. Moxifloxacin tested against the three susceptible isolates showed an initial rapid decrease in colony counts with a >3 log 10 decrease in cfu/mL at 4 h that persisted for 24 h. However at 48 h, one susceptible isolate repopulated to 10 9 cfu/mL in the presence of moxifloxacin (data not shown). The five MRSA isolates that tested intermediate to moxifloxacin by Etest were resistant to this drug by time-kill studies. All isolates were resistant to amoxicillin/ clavulanate at 24 h.
To gain insight into the efficacy of dual therapy against MRSA, we tested six different combination regimens. Five of these contained rifampicin, an oral agent often used in combination to treat S. aureus infection. The addition of a second antibiotic yielded an indifferent effect for all combinations except for the combination of trimethoprim/sulfamethoxazole and rifampicin, which showed a trend towards antagonism (Table 1) . There were no differences in the bactericidal effect of the antimicrobial combinations when CA-and HA-MRSA isolates were compared (data not shown).
Discussion
The present study represents the first in vitro evaluation of the bactericidal efficacy of orally available antimicrobials alone and in combination against MRSA that specifically includes a comparison of CA-and HA-MRSA isolates. Physicians are being faced with increasing numbers of patients for whom oral anti-MRSA therapy is indicated. Also, in illnesses such as osteomyelitis prolonged oral antibiotic therapy is often utilized after an initial course of parenteral antibiotics.
We found that the in vitro bactericidal activity of trimethoprim/sulfamethoxazole against MRSA was significantly better than that of linezolid, rifampicin, clindamycin or minocycline, which are the other major oral antibiotics active against MRSA. Moxifloxacin was more rapidly bactericidal than trimethoprim/sulfamethoxazole at the 4 and 8 h time-point. However, at 24 h there was no difference in the bactericidal activity of moxifloxacin when compared with trimethoprim/ sulfamethoxazole (P = 0.8). The use of moxifloxacin alone for MRSA infections is limited by the low rate of susceptibility and, perhaps even more importantly, by the rapid one-step emergence of resistance among putatively susceptible isolates, as shown at 48 h in one of the three isolates we studied. Our findings are consistent with other time-kill studies of trimethoprim/sulfamethoxazole against resistant S. aureus. 5 Combinations of the various antibiotics with rifampicin did not increase in vitro activity. Specifically, adding rifampicin to trimethoprim/sulfamethoxazole, a common clinical practice, showed a trend towards antagonism. A limitation of our study is the clonal relatedness within both CAand HA-MRSA as revealed by PFGE. However, variability in the antimicrobial susceptibility pattern and the epidemiological unrelatedness of the isolates suggest that the strains were not identical. As expected, the CA and HA clones were unrelated.
We were unable to find prospective studies of trimethoprim/ sulfamethoxazole in treating patients with MRSA infections of skin and soft tissue. Extensive study of S. aureus early in the antibiotic era showed a good correlation between in vitro bactericidal effect and successful treatment in vivo. 6 More recent results, however, have cast doubt on the relationship between in vitro killing and in vivo efficacy for the treatment of S. aureus infections. For example, despite having less killing in vitro, vancomycin was shown to be superior to trimethoprim/ sulfamethoxazole for the treatment of endocarditis and septic thrombophlebitis in intravenous drug users. 7 However, for unclear reasons all treatment failures in the study were in patients with methicillin-susceptible S. aureus infection. Similarly, while linezolid has only a modest killing effect on S. aureus in vitro, clinical studies suggest that linezolid may be as effective as vancomycin in treating MRSA skin and soft-tissue infections. 8 Finally, while combination therapy with rifampicin has consistently shown indifference or antagonism in vitro, limited clinical data suggest treatment efficacy for S. aureus infections when rifampicin is added. 9 This is most convincingly demonstrated in the case of fluoroquinolones and rifampicin in combination, which successfully eradicate S. aureus in the presence of a foreign body. 9 Such conflict between in vitro and in vivo data underscores the need for clinical trials in the treatment of S. aureus infections now that resistance to b-lactam antibiotics is widespread. A recent survey of CA-MRSA infections in three US states found that 97% of isolates were still susceptible to trimethoprim/sulfamethoxazole. 10 There is marked financial impact of widespread oral treatment of MRSA with drugs such as linezolid. The average wholesale cost of a 10 day course of linezolid is US$1352, as compared with US$18 for trimethoprim/sulfamethoxazole (average wholesale price McKesson; Prime Vendor). In light of the ongoing pressures on physicians to deliver effective but economic care, the tremendous cost disparities between oral treatment options makes the need for clinical data even more compelling. At the present time, the high rate of susceptibility of MRSA to trimethoprim/sulfamethoxazole, its bactericidal activity and its excellent bioavailability along with low cost make trimethoprim/ sulfamethoxazole a good option for the oral treatment of susceptible MRSA infections.
